Development of natural polymers-based inhaled microspheres for tuberculosis

IF 0.5 Q4 EDUCATION, SCIENTIFIC DISCIPLINES

Pharmacy Education Pub Date : 2024-05-01 DOI:10.46542/pe.2024.243.123128

Yotomi Desia Eka Rani, M. Rahmadi, D. Hariyadi

{"title":"Development of natural polymers-based inhaled microspheres for tuberculosis","authors":"Yotomi Desia Eka Rani, M. Rahmadi, D. Hariyadi","doi":"10.46542/pe.2024.243.123128","DOIUrl":null,"url":null,"abstract":"Background: Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (Mtb) that mainly affects the lungs (pulmonary TB). Treatment involves a 6-month regimen of four first-line anti-TB drugs: isoniazid (INH), rifampicin (RIF), ethambutol (ETH), and pyrazinamide (PZA). However, the effectiveness of this regimen is limited due to the protection of Mtb bacteria in lung lesions. An alternative approach involves delivering the drugs directly to the lungs through inhalation using innovative methods of microspheres, which can greatly enhance treatment efficacy.\nObjective: This review focuses on inhaled microspheres that use natural polymers for anti-tubercular drugs. \nMethod: A comprehensive literature survey was pulled from databases (PubMed, Scopus, Google Scholar, and ScienceDirect) from 2012 to 2022.\nResult: The characterisation studies, formulation technique, and efficacy using in vitro and in vivo studies of anti-tuberculosis drugs inhaled microspheres.\nConclusion: Microspheres have substantial potential as an inhaled drug delivery system and are likely to have significant clinical contributions in the future.","PeriodicalId":19944,"journal":{"name":"Pharmacy Education","volume":null,"pages":null},"PeriodicalIF":0.5000,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacy Education","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.46542/pe.2024.243.123128","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"EDUCATION, SCIENTIFIC DISCIPLINES","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Tuberculosis (TB) is a contagious disease caused by Mycobacterium tuberculosis (Mtb) that mainly affects the lungs (pulmonary TB). Treatment involves a 6-month regimen of four first-line anti-TB drugs: isoniazid (INH), rifampicin (RIF), ethambutol (ETH), and pyrazinamide (PZA). However, the effectiveness of this regimen is limited due to the protection of Mtb bacteria in lung lesions. An alternative approach involves delivering the drugs directly to the lungs through inhalation using innovative methods of microspheres, which can greatly enhance treatment efficacy. Objective: This review focuses on inhaled microspheres that use natural polymers for anti-tubercular drugs. Method: A comprehensive literature survey was pulled from databases (PubMed, Scopus, Google Scholar, and ScienceDirect) from 2012 to 2022. Result: The characterisation studies, formulation technique, and efficacy using in vitro and in vivo studies of anti-tuberculosis drugs inhaled microspheres. Conclusion: Microspheres have substantial potential as an inhaled drug delivery system and are likely to have significant clinical contributions in the future.

查看原文本刊更多论文

开发治疗结核病的天然聚合物吸入式微球

背景：结核病（TB）是一种由结核分枝杆菌（Mtb）引起的传染性疾病，主要影响肺部（肺结核）。治疗包括为期 6 个月的四种一线抗结核药物疗法：异烟肼 (INH)、利福平 (RIF)、乙胺丁醇 (ETH) 和吡嗪酰胺 (PZA)。然而，由于肺部病变中的 Mtb 细菌的保护作用，这种疗法的效果有限。另一种方法是使用创新的微球方法，通过吸入将药物直接送入肺部，这样可以大大提高疗效：本综述主要介绍使用天然聚合物的抗结核药物吸入微球。方法：从数据库（PubMed、Scopus、Google Scholar 和 ScienceDirect）中提取了 2012 年至 2022 年的全面文献：结果：抗结核药物吸入微球的表征研究、配制技术、体外和体内疗效研究：微球作为一种吸入式给药系统具有巨大的潜力，未来很可能在临床上做出重大贡献。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Pharmacy Education EDUCATION, SCIENTIFIC DISCIPLINES-

CiteScore

0.80

自引率

20.00%

发文量

174

期刊介绍： Pharmacy Education journal provides a research, development and evaluation forum for communication between academic teachers, researchers and practitioners in professional and pharmacy education, with an emphasis on new and established teaching and learning methods, new curriculum and syllabus directions, educational outcomes, guidance on structuring courses and assessing achievement, and workforce development. It is a peer-reviewed online open access platform for the dissemination of new ideas in professional pharmacy education and workforce development. Pharmacy Education supports Open Access (OA): free, unrestricted online access to research outputs. Readers are able to access the Journal and individual published articles for free - there are no subscription fees or ''pay per view'' charges. Authors wishing to publish their work in Pharmacy Education do so without incurring any financial costs.